Valsartan for the treatment of heart failure

Expert Opinion on Pharmacotherapy

Volumn 5, Issue 1, 2004, Pages 181-193

  Latini, Roberto ^a   Masson, Serge ^a   Staszewsky, Lidia ^a   Maggioni, Aldo P ^b  

^a Ist Ricerche Farmacol Mario Negri ^*  (Italy)

^b ANMCO RESEARCH CENTER   (Italy)

Author keywords

Angiotensin receptor blocker; Clinical trial; Enchocardiography; Heart failure; Neurohormones; Quality of life; Valsartan

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; AMLODIPINE; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN 2 RECEPTOR; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CANDESARTAN; CAPTOPRIL; CIMETIDINE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; EPLERENONE; FUROSEMIDE; GLIBENCLAMIDE; HYDROCHLOROTHIAZIDE; INDOMETACIN; LOSARTAN; NEUROHORMONE; NORADRENALIN; PLACEBO; RENIN; VALSARTAN; WARFARIN;

BLOOD PRESSURE REGULATION; CLINICAL TRIAL; COUGHING; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG ERUPTION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG SELECTIVITY; EVIDENCE BASED MEDICINE; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICLE REMODELING; HORMONAL REGULATION; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; HYPOTENSION; KIDNEY DYSFUNCTION; MEDICAL DECISION MAKING; MORBIDITY; MORTALITY; PATHOPHYSIOLOGY; PROGNOSIS; QUALITY OF LIFE; RECEPTOR BLOCKING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK MANAGEMENT; SYMPTOM; TASTE DISORDER; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BENZIMIDAZOLES; CLINICAL TRIALS; DRUG THERAPY, COMBINATION; HEART FAILURE, CONGESTIVE; HUMANS; LOSARTAN; TETRAZOLES; TREATMENT OUTCOME; VALINE;

EID: 0346025503     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.5.1.181     Document Type: Review

References (62)

1. LEVY D, KENCHAIAH S, LARSON MG et al.: Long-term trends in the incidence of and survival with heart failure. N. Engl. J. Med. (2002) 347(18):1397-1402.
2. HO KK, PINSKY JL, KANNEL WB, LEVY D: The epidemiology of heart failure: the Framingham Study. J. Am. Coll. Cardiol. (1993) 22(4 Suppl. A):6A-13A.
3. COWIE MR. WOOD DA, COATS AJ et al.: Incidence and aetiology of heart failure a population-based study. Eur. Heart J. (1999) 20(6):421-428.
4. PULIGNANO G, DEL SINDACO D, TAVAZZI L et al.: Clinical features and outcomes of elderly outpatients with heart failure followed up in hospital cardiology units: data from a large nationwide cardiology database (IN-CHF Registry). Am. Heart J. (2002) 143(1):45-55.
5. CLELAND JG, SWEDBERG K, FOLLATH F et al.: The EuroHeart Failure survey programme - a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur. Heart J. (2003) 24(5):442-463.
6. DI LENARDA A, SCHERILLO M, MAGGIONI AP et al.: Current presentation and management of heart figure in cardiology and internal medicine hospital units: a tale of two worlds - The TEMISTOCLE study. Am. Heart J. (2003) 146:e12.
7. UNGER T: The role of the reninangiotensin system in the development of cardiovascular disease. Am. J. Cardiol. (2002) 89(2A):3A-9A.
8. HORIUCHI M, AKISHITA M, DZAU VJ: Recent progress in angiotensin II Type 2 receptor research in the cardiovascular system. Hypertension (1999) 33:613-621.
9. STROTH U, UNGER T: The reninangiotensin system and its receptors. J. Cardiovasc. Pharmacol. (1999) 33(Suppl. 1):S21-S28.
10. DE MELLO WC, DANSER AH: Angiotensin II and the heart: on the intracrine renin-angiotensin system. Hypertension (2000) 35(6):1183-1188.
11. CAREY RM, WANG ZQ, SIRAGY HM: Role of the angiotensin Type 2 receptor in the regulation of blood pressure and renal function. Hypertension (2000) 35(1 Pt 2):155-163.
12. KAJSTURA J, CIGOLA E, MALHOTRA A et al.: Angiotensin II induces apoptosis of adult ventricular myocytes in vitro. J. Molec. Cell. Cardiol. (1997) 29:859-870.
13. DE ANGELIS N, FIORDALISO F, LAITNI R et al.: Appraisal of the role of angiotensin II and aldosterone in ventricular myocyte apoptosis in adult normotensive rat. J. Mol. Cell Cardiol. (2002) 34:1655-1665.
14. 2 receptors.
15. BLACK HR, GRAFF A, SHUTE D et al.: Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril. J. Hum. Hypertens. (1997) 11(8):483-489.
16. HOLWERDA NJ, FOGARI R, ANGELI P et al.: Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril. J. Hypertens. (1996) 14(9):1147-1151.
17. MOGENSEN CF, NELDAM S, TIKKANEN I et al.: Randomised controlled trial of dual blockade of reninangiotensin system in patients with hypertension, microalbuminuria, and noninsulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. Br. Med. J. (2000) 321(7274):1440-1444.
18. NEUTEL JM, FRISHMAN WH, OPARIL S, PAPADEMITRIOU V, GUTHRIE G: Comparison of telmisartan with lisinopril in patients with mild-to-moderate hypertension. Am J. Ther. (1999) 6(3):161-166.
19. ELLIOTT WJ: Double-blind comparison of eprosartan and enalapril on cough and blood pressure in unselected hypertensive patients. Eprosartan Study Group. J. Hum. Hypertens. (1999) 13(6):413-417.
20. DE GASPARO M, WHITEBREAD S: Binding of valsartan to mammalian angiotensin AT1 receptors. Regul. Pept. (1995) 59(3):303-311.
21. LORELL BH: Role of angiotensin AT1, and AT2 receptors in cardiac hypertrophy and disease. Am. J. Cardiol. (1999) 83(12A):48H-52H.
22. WAGENAAR LJ, VOORS AA, BUIKEMA H, VAN GILST WH: Angiotensin receptors in the cardiovascular system. Can. J. Cardiol. (2002) 18(12):1331-1339.
23. DE GASPARO M, HESS P, NUESSLEIN-HILDESHEIM B, BRUNEVAL P, CLOZEL JP: Combination of non-hypotensive doses of valsartan and enalapril improves survival of spontaneously hypertensive rats with endothelial dysfunction. J. Renin Angiotensin Aldosterone Syst. (2000) 1(2):151-158.
24. MANCINI GB: Emerging role of angiotensin II Type 1 receptor blockers for the treatment of endothelial dysfunction and vascular inflammation. Can. J. Cardiol. (2002) 18(12):1309-1316.
25. MARKHAM A, GOA KL: Valsartan. A review of its pharmacology and therapeutic use in essential hypertension. Drugs (1997) 54(2)199-311.
26. THURMANN PA. Valsartan: a novel angiotensin Type 1 receptor antagonist. Expert Opin. Pharmacother. (2000) 1(2):337-350.
27. CRISCIONE L, BRADLEY WA. BUHLEMAYER P et al.: Valsartan: preclinical and clinical profile of an antihypertensive angiotensin-II antagonist. Cardiovasc. Drug Rev. (1995) 13:230-250.
28. PITT B, SEGL, R, MARTINEZ FA et al.: ELITE Study Investigators, Randomised trial of losartan versus captopril in patients over 65 with heart failure. Lancet (1997) 349:747-752.
29. PITT B, POOLE-WILSON PA, SEGAL R et al.: Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial- the Losartan Heart Failure Survival Study ELITE II. Lancet (2000) 355:1582-1587.
30. KAWAMURA M, IMANASHI M, MATSUSHIMA Y, ITO K, HIRAMORI K: Circulating angiotensin II levels under repeated administration of lisinopril in normal subjects. Clin. Exp. Pharmacol. Physiol. (1992) 19:547-553.
31. JORDE UP, ENNEZAT PV, LISKER J et al.: Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure. Circulation (2000) 101:844-846.
32. ZORNOFF LA, PAIVA SA, MATSUBARA BB, MATSUBARA LS, SPADARO J: Combination therapy with angiotensin convening enzyme inhibition and AT1 receptor inhibitor on ventricular remodeling after myocardial infarction in rats. J. Cardiovasc. Pharmacol. Ther. (2000) 5(3):203-209.
33. BURNIER M: Angiotensin II Type 1 receptor blockers. Circulation (2001) 103(6):904-912.
34. PATTERSON JH: Angiotensin II receptor blockers in heart failure. Pharmacotherapy (2003) 23(2):173-182.
35. PETERSON RC, DUNLAP ME: Angiotensin II receptor blockers in the treatment of heart failure. Congest. Heart Fail. (2002) 8(5):246-250.
36. DICKSTEIN Y, ELITE II and Val-HeFT are different trials: together what do they tell us? Curr. Control Trids Cardiovasc. Med. (2001) 2(5):240-243.
37. HAMROFF G, KATZ SD, MANCINI D et al.: Addition of angiotensin II receptor blockade to maximal angiotensin-converting enzyme inhibition improves exercise capacity in patients with severe congestive heart failure. Circulation (1999) 99(8):990-992.
38. MCKELVIE RS, YUSUF S, PERICAK D et al.: Comparison of candesartan, enalapril, and their combination in congestive heart figure: Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) pilot study. Circulation (1999) 100:1056-1064.
39. BARUCH L, ANAND I, COHEN IS, ZIESCHE S, JUDD D, COHN JN: Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Vasodilator Heart Failure Trial (V-HeFT) Study Group. Circulation (1999) 99(20):2658-2664.
40. COHN JN, TOGNONI G: A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N. Engl. J. Med. (2001) 345(23):1667-1675.
41. COHN JN, TOGNONI G, GLAZER R, SPORMANN D: Baseline demographics of the Valsartan Heart Failure Trial. Val-HeFT Investigators. Eur. J. Heart Fail. (2000) 2(4):439-446.
42. COHN JN, TOGNONI G, GLAZER RD, SPORMANN D, HESTER A: Rationale and design of the Valsartan Heart Failure Trial: a large multinational trial to assess the effects of valsartan, an angiotensin-receptor blocker, on morbidity and mortality in chronic congestive heart failure. J. Card. Fail. (1999) 5(2):155-160.
43. TAVAZZI L, PINA I, CHIANG Yr et al.: Association of quality of life with improved clinical outcomes: results from the valsartan heart failure trial. J. Am. Coll. Cardiol. (2002) 39(5):167A.
44. FRANCIS GS, COHN JN, JOHNSON G, RECTOR IS, GOLDMAN S, SIMON A, FOR THE V-HEFT VA COOPERATIVE STUDIES GROUP: Plasma norepinephrine, plasma renin activity, and congestive heart failure. Relations to survival and the effects of therapy in V-HeFT II. Circulation (1993) 87(VI) 40-48.
45. KOGLIN J, PEHLIVANLI S, SCHWAIBLMAIR M, VOGESER, M, CREMER P, VON SCHEIDT W: Role of brain natriuretic peptide in risk stratification of patients with congestive heart failure. J. Am. Coll. cardiol. (2001) 38:1934-1941.
46. BENEDICT CR, SHELTON B, JOHNSTONE DE et al.: Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. Circulation (1996) 94:690-697.
47. LATINI R, MASSON S, DE ANGELIS N, ANAND I: Role of brain natriuretic peptide in the diagnosis and management of heart failure: current concepts. J. Card. Fail. (2002) 8(5):288-299.
48. LATINI R. MASSON S, ANAND I et al.: Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT). Circulation (2002) 106(19):2454-2458.
49. ANAND IS, FISHER LD, CHIANG YT et al.: Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT. Circulation (2003) 107(9):1278-1283.
50. COHN JN, ANAND IS, LATINI R. et al.: Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure. Results from the Valsartan Heart Failure Trial. Circulation (2003) 108:r61-r64.
51. WONG M, STASZEWSKY L, LATINI R et al: Valsartan benefits left ventricular structure and function in heart failure: Val-HeFT echocardiographic study. J. Am. Coll. Cardiol. (2002) 40(5):970-975.
52. WONG M, STASZEWSKY L, ANAND I, FELICIANO N, HESTER A, COHN JN: Stratification of baseline left ventricular dimensions and ejection fraction determines response to valsartan in heart failure. Val-HeFT echocardiographic study. Circulation (2002) 106(19)(Suppl.):II-5-11-2.
53. MASSIE BM: Neurohormonal blockade in chronic heart failure. How much is enough? Can there be too much? J. Am. Coll. Cardiol. (2002) 39(1):79-82.
54. PITT B, REMME W, ZANNAD F et al. FOR THE EPLERENONE POST-ACUTE MYOCARDIAL INFARCT[ON HEART FAILURE EFFICACY AND SURVIVAL STUDY INVESTIGATORS: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. New Engl. J. Med. (2003) 348:1309-1321.
55. MCMURRAY JJV, OSTERGREN J, SWEDBERG K et al.: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet (2003) 362(9386):767-771.
56. MCKELVIE RS, ROULEAU JL, WHITE M et al.: Comparative impact of enalapril, candesartan or metoprolol alone or in combination on ventricular remodelling in patients with congestive heart failure. Ear. Heart J. (2003) 24:1727-1734.
57. MAGGIONI AP, ANAND I, GOTTLIEB SO, LATINI R, TOGNONI G, COHN JN: Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. J. Am. Coll Cardiol. (2002) 40(8):1414-1421.
58. THE CONSENSUS TRIAL STUDY GROUP: Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). New Engl. J. Med. (1987) 316:1429-1435.
59. BART BA, ERTL G, HELD P et al.: Contemporary management of patients with left ventricular systolic dysfunction. Results from the Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE) Registry. Eur. Heart J. (1999) 20(16):1182-1190.
60. GRANGER CB, McMURRAY JJV, YUSUF S et al.: Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet (2003) 362(9386):772-776.
61. PFEFFER MA. MCMURRAY JJV, VELAZQUEZ EJ et al.: Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. New Engl. J. Med. (2003) 349:1893-1906.
62. PFEFFER MA, SWEDBERG K, GRANGER CB et al.: Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet (2003) 362(9386):759-766.